 |
6 Diseases |  |
0 Trials |
|
0 Trials |  |
13 News |  |
- | TNFcept (etanercept biosimilar) / LG Chem, Mochida
Retrospective data, Journal: Comparative efficacy and safety of etanercept biosimilars in comparison with etanercept in patients with rheumatoid arthritis who have insufficient response to methotrexate: A network meta-analysis. (Pubmed Central) - Nov 21, 2021
No significant difference was found between etanercept biosimilars and etanercept originators in patients with active RA despite treatment with MTX in terms of the ACR20 response rate and SAEs.
- | Davictrel (etanercept biosimilar) / Hanwha Solutions
Trial completion, Trial primary completion date: Safety and Pharmacokinetic Characteristics of HD203 Liquid in Healthy Male Volunteers (clinicaltrials.gov) - Jul 14, 2016
P1, N=48, Completed, Sponsor: Hanwha Chemical
No significant difference was found between etanercept biosimilars and etanercept originators in patients with active RA despite treatment with MTX in terms of the ACR20 response rate and SAEs. Active, not recruiting --> Completed | Trial primary completion date: Feb 2015 --> Dec 2015
- Davictrel (etanercept biosimilar) / Hanwha Solutions
Trial primary completion date: Safety and Pharmacokinetic Characteristics of HD203 Liquid in Healthy Male Volunteers (clinicaltrials.gov) - Jul 15, 2014
P1, N=48, Active, not recruiting, Sponsor: Hanwha Chemical
Active, not recruiting --> Completed | Trial primary completion date: Feb 2015 --> Dec 2015 Trial primary completion date: Dec 2013 --> Feb 2015
- Davictrel (etanercept biosimilar) / Hanwha Solutions
Enrollment change: SPH: Safety and Pharmacokinetic Characteristics of HD203 in Healthy Male Volunteers (clinicaltrials.gov) - Jul 15, 2014
P1, N=42, Completed, Sponsor: Hanwha Chemical
Trial primary completion date: Dec 2013 --> Feb 2015 N=35 --> 42
- ||||||| Davictrel (etanercept biosimilar) / Hanwha Solutions
Trial completion, Combination therapy: Randomized Double-blind Parallel Trial to Evaluate Equivalence in Efficacy and Safety of HD203 and Enbrel in RA Patients (clinicaltrials.gov) - Jul 15, 2014
P3, N=294, Completed, Sponsor: Hanwha Chemical
N=35 --> 42 Active, not recruiting --> Completed
- Davictrel (etanercept biosimilar) / Hanwha Solutions
Enrollment closed: Safety and Pharmacokinetic Characteristics of HD203 Liquid in Healthy Male Volunteers (clinicaltrials.gov) - Nov 9, 2013
P1, N=48, Active, not recruiting, Sponsor: Hanwha Chemical
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Davictrel (etanercept biosimilar) / Hanwha Solutions
New P1 trial: Safety and Pharmacokinetic Characteristics of HD203 Liquid in Healthy Male Volunteers (clinicaltrials.gov) - Jul 8, 2013
P1, N=48, Active, not recruiting, Sponsor: Hanwha Chemical
- | Davictrel (etanercept biosimilar) / Hanwha Solutions
Trial completion: Safety and Pharmacokinetic Characteristics of HD203 Liq. in Healthy Subjects (clinicaltrials.gov) - Jul 2, 2013
P1, N=44, Completed, Sponsor: Hanwha Chemical
Recruiting --> Active, not recruiting Recruiting --> Completed
- | Davictrel (etanercept biosimilar) / Hanwha Solutions
New P1 trial: Safety and Pharmacokinetic Characteristics of HD203 Liq. in Healthy Subjects (clinicaltrials.gov) - Sep 7, 2011
P1, N=44, Completed, Sponsor: Hanwha Chemical
- ||||| Davictrel (etanercept biosimilar) / Hanwha Solutions
Enrollment closed, Combination therapy: Randomized Double-blind Parallel Trial to Evaluate Equivalence in Efficacy and Safety of HD203 and Enbrel in RA Patients (clinicaltrials.gov) - Sep 6, 2011
P3, N=300, Active, not recruiting, Sponsor: Hanwha Chemical
Recruiting --> Completed Not yet recruiting --> Active, not recruiting